• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在抗原呈递过程中调节共刺激以增强癌症免疫疗法

MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY.

作者信息

Liechtenstein Therese, Dufait Ines, Lanna Alessio, Breckpot Karine, Escors David

机构信息

Division of Infection and Immunity. Rayne Institute. University College London. 5 University Street. WC1E 6JF. London. United Kingdom.

出版信息

Immunol Endocr Metab Agents Med Chem. 2012 Sep;12(3):224-235. doi: 10.2174/187152212802001875.

DOI:10.2174/187152212802001875
PMID:22945252
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3428911/
Abstract

One of the key roles of the immune system is the identification of potentially dangerous pathogens or tumour cells, and raising a wide range of mechanisms to eliminate them from the organism. One of these mechanisms is activation and expansion of antigen-specific cytotoxic T cells, after recognition of antigenic peptides on the surface of antigen presenting cells such as dendritic cells (DCs). However, DCs also process and present autoantigens. Therefore, antigen presentation has to occur in the appropriate context to either trigger immune responses or establishing immunological tolerance. This is achieved by co-stimulation of T cells during antigen presentation. Co-stimulation consists on the simultaneous binding of ligand-receptor molecules at the immunological synapse which will determine the type and extent of T cell responses. In addition, the type of cytokines/chemokines present during antigen presentation will influence the polarisation of T cell responses, whether they lead to tolerance, antibody responses or cytotoxicity. In this review, we will focus on approaches manipulating co-stimulation during antigen presentation, and the role of cytokine stimulation on effective T cell responses. More specifically, we will address the experimental strategies to interfere with negative co-stimulation such as that mediated by PD-L1 (Programmed cell death 1 ligand 1)/PD-1 (Programmed death 1) to enhance anti-tumour immunity.

摘要

免疫系统的关键作用之一是识别潜在危险的病原体或肿瘤细胞,并启动多种机制将它们从机体中清除。其中一种机制是在识别抗原呈递细胞(如树突状细胞,DC)表面的抗原肽后,激活并扩增抗原特异性细胞毒性T细胞。然而,DC也会处理和呈递自身抗原。因此,抗原呈递必须在适当的背景下发生,以触发免疫反应或建立免疫耐受。这是通过抗原呈递过程中对T细胞的共刺激来实现的。共刺激包括配体-受体分子在免疫突触处的同时结合,这将决定T细胞反应的类型和程度。此外,抗原呈递过程中存在的细胞因子/趋化因子类型将影响T细胞反应的极化,即它们是否导致耐受、抗体反应或细胞毒性。在本综述中,我们将重点关注在抗原呈递过程中操纵共刺激的方法,以及细胞因子刺激对有效的T细胞反应的作用。更具体地说,我们将探讨干扰负性共刺激(如由程序性细胞死亡1配体1/程序性死亡1,PD-L1/PD-1介导的负性共刺激)以增强抗肿瘤免疫力的实验策略。

相似文献

1
MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY.在抗原呈递过程中调节共刺激以增强癌症免疫疗法
Immunol Endocr Metab Agents Med Chem. 2012 Sep;12(3):224-235. doi: 10.2174/187152212802001875.
2
Dendritic Cell-Targeted Nanoparticles Enhance T Cell Activation and Antitumor Immune Responses by Boosting Antigen Presentation and Blocking PD-L1 Pathways.树突状细胞靶向纳米颗粒通过增强抗原呈递和阻断 PD-L1 通路来增强 T 细胞激活和抗肿瘤免疫反应。
ACS Appl Mater Interfaces. 2024 Oct 9;16(40):53577-53590. doi: 10.1021/acsami.4c12821. Epub 2024 Sep 30.
3
PD-L1/PD-1 Co-Stimulation, a Brake for T cell Activation and a T cell Differentiation Signal.程序性死亡配体1/程序性死亡受体1共刺激,T细胞活化的制动器和T细胞分化信号
J Clin Cell Immunol. 2012 Oct 30;S12. doi: 10.4172/2155-9899.S12-006.
4
Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells.抗原呈递过程中干扰 PD-L1/PD-1 共刺激可增强抗原特异性 T 细胞的多功能性。
Gene Ther. 2014 Mar;21(3):262-71. doi: 10.1038/gt.2013.80. Epub 2014 Jan 9.
5
Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.接受树突状细胞免疫治疗的乳腺癌Balb/C小鼠淋巴结中树突状细胞和T细胞的表型特征
Immunol Lett. 2016 Sep;177:25-37. doi: 10.1016/j.imlet.2016.07.009. Epub 2016 Jul 14.
6
Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.针对抗原呈递细胞中的 LAG-3 和 PD-1 以增强 T 细胞的激活。
Front Immunol. 2018 Feb 27;9:385. doi: 10.3389/fimmu.2018.00385. eCollection 2018.
7
Induction of Interleukin-10 Producing Dendritic Cells As a Tool to Suppress Allergen-Specific T Helper 2 Responses.诱导白细胞介素-10 产生树突状细胞作为抑制变应原特异性辅助性 T 细胞 2 型反应的一种工具。
Front Immunol. 2018 Mar 19;9:455. doi: 10.3389/fimmu.2018.00455. eCollection 2018.
8
Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.阻断免疫检查点分子可提高树突状细胞疫苗的 T 细胞启动潜能。
Immunology. 2020 Jan;159(1):75-87. doi: 10.1111/imm.13126. Epub 2019 Oct 24.
9
Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.从树突状细胞中去除唾液酸可改善抗原交叉呈递并增强抗肿瘤免疫反应。
Oncotarget. 2016 Jul 5;7(27):41053-41066. doi: 10.18632/oncotarget.9419.
10
Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.抗原呈递细胞上的程序性死亡配体1促进抗原特异性细胞毒性T淋巴细胞的诱导:在过继性T细胞免疫治疗中的应用。
J Immunother. 2016 Oct;39(8):306-15. doi: 10.1097/CJI.0000000000000136.

引用本文的文献

1
Immune Checkpoint Molecules in Hodgkin Lymphoma and Other Hematological Malignancies.霍奇金淋巴瘤及其他血液系统恶性肿瘤中的免疫检查点分子
Cancers (Basel). 2025 Jul 10;17(14):2292. doi: 10.3390/cancers17142292.
2
Regulatory mechanisms of PD-1/PD-L1 in cancers.PD-1/PD-L1 在癌症中的调控机制。
Mol Cancer. 2024 May 18;23(1):108. doi: 10.1186/s12943-024-02023-w.
3
Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes.通过靶向叶酸受体 α 的 CD28/CD40 嵌合共刺激抗原受体(CoStAR™)信号转导增强 T 细胞活性并增强肿瘤浸润淋巴细胞的肿瘤反应性。
Front Immunol. 2023 Nov 7;14:1256491. doi: 10.3389/fimmu.2023.1256491. eCollection 2023.
4
A Triple High Throughput Screening for Extracellular Vesicle Inducing Agents With Immunostimulatory Activity.具有免疫刺激活性的细胞外囊泡诱导剂的三重高通量筛选
Front Pharmacol. 2022 Apr 11;13:869649. doi: 10.3389/fphar.2022.869649. eCollection 2022.
5
Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer.现代放疗与免疫疗法在转移性前列腺癌治疗中的相互作用
Front Oncol. 2021 Sep 14;11:744679. doi: 10.3389/fonc.2021.744679. eCollection 2021.
6
Endogenous TLR2 ligand embedded in the catalytic region of human cysteinyl-tRNA synthetase 1.内源性 TLR2 配体嵌入到人半胱氨酰-tRNA 合成酶 1 的催化结构域中。
J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2019-000277.
7
Harnessing the potential of multimodal radiotherapy in prostate cancer.挖掘多模态放射治疗在前列腺癌中的潜力。
Nat Rev Urol. 2020 Jun;17(6):321-338. doi: 10.1038/s41585-020-0310-3. Epub 2020 May 1.
8
Triggered Immune Response Induced by Antigenic Epitopes Covalently Linked with Immunoadjuvant-Pulsed Dendritic Cells as a Promising Cancer Vaccine.抗原表位共价连接免疫佐剂脉冲树突状细胞引发的免疫应答作为一种有前途的癌症疫苗。
J Immunol Res. 2020 Apr 4;2020:3965061. doi: 10.1155/2020/3965061. eCollection 2020.
9
Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?免疫化疗能否缓解癌细胞对免疫检查点抑制剂的耐药性?
Front Immunol. 2019 May 29;10:1181. doi: 10.3389/fimmu.2019.01181. eCollection 2019.
10
CD1d highly expressed on DCs reduces lung tumor burden by enhancing antitumor immunity.树突状细胞高表达 CD1d 可通过增强抗肿瘤免疫来减少肺部肿瘤负担。
Oncol Rep. 2019 May;41(5):2679-2688. doi: 10.3892/or.2019.7037. Epub 2019 Feb 28.

本文引用的文献

1
Ipilimumab in the treatment of melanoma.易普利姆玛治疗黑色素瘤。
Expert Opin Biol Ther. 2012 Jun;12(6):773-82. doi: 10.1517/14712598.2012.675325. Epub 2012 Apr 14.
2
Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.在 B16 黑色素瘤模型中,当 CTLA-4 阻断剂单药治疗无活性时,与肿瘤靶向超抗原联合使用会大大增强抗肿瘤作用。
J Immunother. 2012 May;35(4):344-53. doi: 10.1097/CJI.0b013e318253ec25.
3
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.同时抑制两种调节性 T 细胞亚群可增强白细胞介素-15 在前列腺肿瘤模型中的疗效。
Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6187-92. doi: 10.1073/pnas.1203479109. Epub 2012 Apr 2.
4
SHARPIN is a key regulator of immune and inflammatory responses.SHARPIN 是免疫和炎症反应的关键调节因子。
J Cell Mol Med. 2012 Oct;16(10):2271-9. doi: 10.1111/j.1582-4934.2012.01574.x.
5
Application of monoclonal antibodies as cancer therapy in solid tumors.单克隆抗体在实体瘤癌症治疗中的应用。
Curr Clin Pharmacol. 2012 May;7(2):137-45. doi: 10.2174/157488412800228929.
6
Ipilimumab: its potential in non-small cell lung cancer.易普利姆玛:在非小细胞肺癌中的应用潜力。
Ther Adv Med Oncol. 2012 Mar;4(2):43-50. doi: 10.1177/1758834011431718.
7
Targeting pattern recognition receptors in cancer immunotherapy.靶向肿瘤免疫治疗中的模式识别受体。
Target Oncol. 2012 Mar;7(1):29-54. doi: 10.1007/s11523-012-0213-1. Epub 2012 Mar 8.
8
Distinct MAPK pathways are involved in IL-23 production in dendritic cells cocultured with NK cells in the absence or presence of angiotensin II.在没有或存在血管紧张素 II 的情况下,与 NK 细胞共培养的树突状细胞中,不同的 MAPK 途径参与了 IL-23 的产生。
Mol Immunol. 2012 May;51(1):51-6. doi: 10.1016/j.molimm.2012.02.004. Epub 2012 Mar 3.
9
SHARPIN is essential for cytokine production, NF-κB signaling, and induction of Th1 differentiation by dendritic cells.SHARPIN 对于细胞因子的产生、NF-κB 信号通路以及树突状细胞诱导 Th1 分化是必不可少的。
PLoS One. 2012;7(2):e31809. doi: 10.1371/journal.pone.0031809. Epub 2012 Feb 14.
10
Current status of immunological approaches for the treatment of prostate cancer.前列腺癌免疫治疗的研究现状。
Curr Opin Urol. 2012 May;22(3):197-202. doi: 10.1097/MOU.0b013e3283519ad5.